# Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus

> **NCT02162550** · PHASE4 · UNKNOWN · sponsor: **Phoenix VA Health Care System** · enrollment: 148 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Bydureon
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02162550
- **Lead sponsor:** Phoenix VA Health Care System
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-06
- **Primary completion:** 2019-04
- **Final completion:** 2019-09
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2018-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02162550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02162550, "Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02162550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*